Spots Global Cancer Trial Database for Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia

Official Title: Somatic Mutations in Stem and Progenitor Cells in AML

Study ID: NCT01251159

Conditions

Leukemia

Interventions

mutation analysis

polymerase chain reaction

immunologic technique

laboratory biomarker analysis

Study Description

Brief Summary: RATIONALE: Studying samples of bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is studying bone marrow samples from patients with acute myeloid leukemia.

Detailed Description: OBJECTIVES: * To rigorously examine fractionated hematopoietic stem and progenitor cells from patients with acute myeloid leukemia (AML). * To define somatic mutations occurring in de novo AML, including the FLT3-ITD, CEBPA, NPM1, TET2, ASXL1, IDH1, and IDH2 mutations. * To examine what cellular compartments (LT-HSC, ST-HSC, CMP, GMP, and MEP) contain the selected mutations and in what order those mutations occur. OUTLINE: Archived bone marrow specimens are analyzed for sequencing and detection of mutations by Sanger-based resequencing of PCR amplicons. Results are then compared with the results of age-matched healthy controls.